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Mutations in theGGCX and ABCC6 Genes in a Family
with Pseudoxanthoma Elasticum-Like Phenotypes
Qiaoli Li1, Dorothy K. Grange2, Nicole L. Armstrong2, Alison J. Whelan2, Maria Y. Hurley3, Mark A. Rishavy4,
Kevin W. Hallgren4, Kathleen L. Berkner4, Leon J. Schurgers5, Qiujie Jiang1 and Jouni Uitto1
A characteristic feature of classic pseudoxanthoma elasticum (PXE), an autosomal recessive disorder caused by
mutations in the ABCC6 gene, is aberrant mineralization of connective tissues, particularly the elastic fibers.
Here, we report a family with PXE-like cutaneous features in association with multiple coagulation factor
deficiency, an autosomal recessive disorder associated with GGCX mutations. The proband and her sister, both
with severe skin findings with extensive mineralization, were compound heterozygotes for missense mutations
in the GGCX gene, which were shown to result in reduced g-glutamyl carboxylase activity and in
undercarboxylation of matrix gla protein. The proband’s mother and aunt, also manifesting with PXE-like skin
changes, were heterozygous carriers of a missense mutation (p.V255M) in GGCX and a null mutation (p.R1141X)
in the ABCC6 gene, suggesting digenic nature of their skin findings. Thus, reduced g-glutamyl carboxylase
activity in individuals either compound heterozygous for a missense mutation in GGCX or with
haploinsufficiency in GGCX in combination with heterozygosity for ABCC6 gene expression results in aberrant
mineralization of skin leading to PXE-like phenotype. These findings expand the molecular basis of PXE-like
phenotypes, and suggest a role for multiple genetic factors in pathologic tissue mineralization in general.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE; OMIM 264800, 177850) is
an autosomal recessive multisystem disorder characterized
by dystrophic mineralization of soft connective tissues,
particularly the elastic fibers, in a number of organs,
including the skin, the eyes, and the arterial blood vessels
(Ringpfeil et al., 2001; Neldner and Struk, 2002; Uitto and
Ringpfeil, 2007; Li et al., 2008). The primary cutaneous
lesions are small, yellowish papules on the predilection sites
at flexural areas, and these lesions progressively coalesce into
larger plaques of inelastic, leathery skin with a yellowish hue.
Histopathology of the affected skin shows accumulation of
pleiomorphic elastotic material in upper and mid dermis,
which is mineralized as visualized by special histopathologic
stains. The eye manifestations consist of angioid streaks, and
bleeding from the retina can result in loss of visual acuity and,
rarely, blindness. The cardiovascular manifestations result
from mineralization of the arterial blood vessels, and include
gastrointestinal bleeding, intermittent claudication, hyperten-
sion and, occasionally, early myocardial infarcts. Although
the disease has considerable morbidity and mortality, the
phenotypic spectrum is highly variable with both inter- and
intra-familial heterogeneity. The precise incidence of this
condition is undefined, but the estimates are in the range of
1 in 50,000–75,000.
Classic PXE is caused by mutations in the ABCC6 gene,
which encodes a putative transmembrane transporter protein,
ABCC6 (also known as multidrug resistance-associated
protein 6), a member of the family of ATP-binding cassette
proteins (Bergen et al., 2000; Le Saux et al., 2000; Ringpfeil
et al., 2000; Miksch et al., 2005; Pfendner et al., 2007). The
ABCC6 gene is primarily expressed in the liver, to a lesser
extent in the proximal tubules of kidneys, and at very low
level, if at all, in tissues affected in PXE (Belinsky and Kruh,
1999; Scheffer et al., 2002; Matsuzaki et al., 2005). Although
the mineral deposits in the affected tissues are known to
consist of calcium and phosphate, the precise mechanisms
leading to aberrant mineralization remain unclear, and
specifically, the substrate specificity of ABCC6 in vivo is
currently unknown.
Occasionally, PXE-like phenotypes have been reported in
association with multiple coagulation factor deficiency
(Rongioletti et al., 1989; Le Corvaisier-Pieto et al., 1996;
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Vanakker et al., 2007), and molecular analysis of some of
these patients revealed mutations in the GGCX gene, which
encodes an enzyme required for g-glutamyl carboxylation of
gla proteins (Vanakker et al., 2007). In this report we detail a
family with PXE-like clinical features, and also with
deficiency of vitamin K-dependent clotting factors, particu-
larly Factor X. Strikingly, this family harbors mutations both in
the GGCX and ABCC6 genes, and combinations of these
mutations in two patients with PXE-like skin phenotype
suggest digenic inheritance.
RESULTS
Clinical findings
The proband (III-3 in Figure 1) is a 16-year-old woman who
was initially evaluated in early childhood because of cardiac
abnormalities, including supravalvular pulmonic stenosis and
peripheral pulmonary artery stenosis. She has undergone two
pulmonary valve replacement procedures. Following an
episode of endocarditis, she had a stroke with vision loss in
the right eye, but rigorous ophthalmologic examination with
respect to angioid streaks has not been reported. She
developed focal segmental glomerulosclerosis, thought to
be immune complex mediated. At around age 10 years, she
began developing progressively loose, sagging and redundant
skin, primarily affecting the neck and trunk, and an initial
diagnosis of cutis laxa was made (Figure 1a–c). She was also
found to have a coagulation disorder with Factor X deficiency
(Table 1). The proband has a 19-year-old sister (III-1) with
similar skin changes beginning in her early teens, as well as a
coagulation disorder; she has had a normal cardiac evalua-
tion. They have a 17-year-old brother (III-2) who is clinically
normal. Examination of other members of the nuclear
pedigree (Figure 1g) showed that the father of the proband
is clinically normal, whereas the mother (II-2), at the age of
40 years, has distinct folding of the skin, particularly in the
axillary areas. She also has characteristic yellowish papules
consistent with PXE on the sides of the neck and in the
axillary areas (Figure 1d). The mother has a fraternal twin
sister (II-3) with similar cutaneous findings (Figure 1e and f).
Neither the mother nor her sister have evidence of a
coagulation disorder (Table 1).
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Figure 1. Cutaneous findings in a family with PXE-like phenotype. Note the loose and sagging skin in the 16-year-old proband (III-3, a–c). The proband’s
mother (II-2, d) and aunt (II-3; e, f), both 40 years of age, demonstrate redundant folding of the skin in the axillary area (d, e) and popliteal fossa (f), as well
as small yellowish papules characteristic of PXE (arrows). The nuclear pedigree of the family with PXE-like skin findings and coagulation factor deficiency (g).
The mutations in the GGCX and ABCC6 genes identified in this family are indicated on the left of panel g. The proband is identified by an arrow.
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Histopathology of the skin from the proband, her sister and
the aunt revealed accumulation of basophilic elastotic
material in the mid dermis, which was demonstrated to
show aberrant mineralization with von Kossa and Alizarin
red special stains (Figure 2). Thus, these patients have clinical
and histopathological features of PXE.
Mutation analyses
Considering the presence of PXE-like cutaneous findings, we
first sequenced the ABCC6 gene. The recurrent mutation,
p.R1141X, which is particularly prevalent (about 30% of all
detected mutations in PXE patients of the European extrac-
tion; Pfendner et al., 2007) was found in the DNA from the
father, mother, the maternal aunt and the younger brother,
but not in the proband herself or her sister (Figures 1g and 3a).
The individuals were heterozygotes for this mutation, and no
other ABCC6 mutation could be disclosed in this family.
Sequencing of the proband’s sister’s and her aunt’s ABCC6
gene revealed the presence of eight heterozygous poly-
morphisms in the exons 7–19. This finding argues against
large allelic deletions at the 50 half of the gene, which might
not be detectable by the mutation detection strategy
employed in our study (Pfendner et al., 2007).
Considering the clinical association of the PXE-like
cutaneous features with coagulation disorder in this family,
we also sequenced the GGCX and VKORC1 genes. The
results demonstrated the presence of two missense mutations
in GGCX. First, a single base transition mutation (c.791G-A)
resulting in substitution of a valine by methionine at position
255 (p.V255M) of the g-glutamyl carboxylase enzyme was
detected (Figure 3b). This mutation was not present in 100
control alleles by restriction enzyme digestion and/or by
direct nucleotide sequencing (Figure 3c). Secondly, a single
nucleotide substitution (c.927C-T) resulting in substitution
of a serine by phenylalanine in position 300 (p.S300F) was
detected (Figure 3d). Direct sequencing of 150 control alleles
detected the S300 codon only, suggesting that this missense
substitution is not a frequent polymorphism. Determination of
the evolutionary sequence conservation of GGCX in different
species revealed that the amino acid corresponding to V255
Table 1. Activities of the coagulation factors and
clinical laboratory values in patients with GGCX gene
mutations
Patient
Laboratory measurement III-1 III-3 II-3 Normal values
F II (%) 43 64 95 60–160
F VII (%) 31 108 86 60–160
F VIII (%) – 67 – 60–160
F IX (%) 56 62 76 60–160
F X (%) 18 33 90 60–160
PTT (s) 32.1 43.3 32.0 25–41
PT (s) 21.6 18.1 10.9 12–15
INR 1.9 1.2 1.1 0.8–1.2
F, factor; INR, international normalized ratio; PT, prothrombin time; PTT,
partial thrombin time.
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Figure 2. Histopathology of the cutaneous lesions in the sister (III-1), the proband (III-3) and aunt (II-3). Staining with hematoxylin-eosin (a–c) demonstrates
basophilic abnormal elastic structures in the mid dermis (arrows). Special stains (von Kossa, d–f; Alizarin red, g–i) reveal that these elastotic structures are
mineralized (arrows). Scale bar¼ 0.1 mm.
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is fully conserved (Figure 3e). In contrast, the serine at
position 300 was less well conserved, several species
depicting proline in this position, although the surrounding
amino-acid sequences were highly conserved. For example,
the sequence homology between the human and mouse 23-
amino-acid sequence segment surrounding the S300 was
95.7% (Figure 3f). Sequencing of the VKORC1 gene did not
disclose any pathogenic mutations.
Genotype/phenotype correlations
A correlation of the clinical findings with the genotypes
revealed that the proband and her sister were compound
heterozygotes for the two GGCX missense mutations,
potentially explaining their hematologic findings (Brenner
et al., 1998; Spronk et al., 2000; Rost et al., 2004b, 2006). In
contrast, the proband’s father, brother, her mother, and the
mother’s twin sister were heterozygous for one of the GGCX
mutations only, designating them as carriers without clinical
hematologic findings (Figure 1g). The latter individuals were
also carriers of the ABCC6 nonsense mutation p.R1141X.
Specifically, the mother and her twin sister were hetero-
zygous for the GGCX missense mutation p.V255M and the
ABCC6 nonsense mutation p.R1141X, suggesting digenic
inheritance of their cutaneous findings. However, the
proband’s younger brother and father were heterozygous
carriers of the p.S300F mutation in the GGCX gene although
they also carried the p.R1141X mutation in the ABCC6 gene;
they did not display any signs of cutaneous findings or
hematologic disorder.
Assay of c-glutamyl carboxylase activity
Previous studies have clearly demonstrated that the p.R1141X
mutation in the ABCC6 gene in heterozygous carriers does
not cause PXE (Wegman et al., 2005; Pfendner et al., 2007).
Similarly, combined coagulation factor deficiency is an
autosomal recessive disease. The proband and her sister
showed milder hematological defects than previously re-
ported in patients with combined deficiency of vitamin K-
dependent coagulation factors, which we postulated might be
because of the type of missense mutations. We ascertained,
therefore, a hypothesis that the missense mutations disclosed
in the GGCX gene in this family may not result in complete
loss of g-carboxylase activity, therefore explaining the milder
hematologic findings in these compound heterozygous
individuals. Consequently, we measured the g-glutamyl
carboxylase activity of recombinant protein expressed from
the wild-type (WT) as well as from mutant alleles harboring
either the p.V255M or the p.S300F mutation.
The g-glutamyl carboxylase activity was measured by
using a small peptide containing the Phe-Leu-Glu-Glu-Leu
sequence as substrate, in the absence of Factor X propeptide.
The assay, which utilizes incorporation of radioactive
[14C]-CO2 to the substrate, revealed clearly measurable
activity with the WT enzyme (Table 2). In contrast, the
mutant protein with the p.V255M mutation showed activity,
which was only about 5% of that noted with the WT protein,
and even more strikingly, essentially no activity (o1%) was
detected with the protein harboring the p.S300F mutation
(Table 2). To further examine the consequences of the
Figure 3. Mutation detection in the family. (a) Identification of the recurrent nonsense mutation p.R1141X in the ABCC6 gene. Note the heterozygous
C-T transition substitution at nucleotide position 3,421 (arrow). (b, d) Identification of missense mutations p.V255M and p.S300F in the GGCX gene. The
sequences shown are in the complementary strand. (c) The presence of the p.V255M mutation in the control population was examined by restriction
enzyme digestion with Apal I. Note that the mutation abolishes the restriction site, resulting in the 243 bp mutant allele, in addition to 163 and 80 bp fragments.
In control individuals the 243 bp PCR product is digested to 163 and 80 bp fragments (m, heterozygous mutant; c, control). (e, f) Evolutionary conservation of the
amino acids V255 (e) and S300 (f) in the g-glutamyl carboxylase protein.
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mutations on the g-glutamyl carboxylase activity, additional
measurements were performed with the same peptide
substrate but also with a Factor X propeptide present in the
reaction. This propeptide serves as the primary binding site
for the carboxylase in Factor X and is conserved in vitamin K-
dependent coagulation factors (Berkner, 2005). In the
presence of the propeptide, the activity of the WT enzyme
increased by about three-fold as compared to that in the
absence of propeptide, whereas the protein with p.S300F
mutation continued to show low, B3% of the WT, activity
(Table 2). In contrast, the activity of the protein harboring the
p.V255M mutation showed little difference (B90%) from the
WT enzyme (Table 2). These observations clearly suggest that
the mutations detected in the GGCX gene in this family
are associated with reduced g-carboxylase activity, but the
reduced activity may result from different mechanisms with
respect to enzyme-substrate interactions.
Reduced c-glutamyl carboxylation of matrix gla protein in the
skin and plasma
To examine the consequences of reduced g-glutamyl
carboxylase activity as a result of GGCX mutations, we next
performed immunohistochemistry of skin biopsies with
antibodies, which distinguish carboxylated and undercar-
boxylated forms of matrix gla protein (cMGP and ucMGP,
respectively), a substrate for the carboxylase activity (Schur-
gers et al., 2005). Staining of skin from the proband (III-3), her
sister (III-1) or her aunt (II-3) revealed an abundance of MGP
in the area of mineralization in the mid dermis, however, this
protein was predominantly in the undercarboxylated form
(ucMGP; Figure 4a–c). In contrast, specimens from normal
unrelated control individuals revealed very little, if any, of
ucMGP in the corresponding areas of dermis (Figure 4d). Low
levels of cMGP both in patients’ skin (Figure 4e–g) and in
control skin (Figure 4h) were present. Thus, the ratio of uc/
cMGP is markedly higher in the patients’ skin, apparently
reflecting reduced g-glutamyl carboxylase activity. Immuno-
staining for two other proteins, fetuin-A and osteonectin,
involved in the mineralization processes (Davies et al., 2006;
Jiang et al., 2007), was also performed (Figure 4). The
presence of both these proteins was noted in the patients’
skin corresponding to the general areas of mineralization
Table 2. c-Glutamyl carboxylase activities of wild-
type and mutant proteins in vitro1
Carboxylase activity
Without propeptide With propeptide
Variant pmol h1 Percent2 pmol h1 Percent2
Wild type 3,649 100 10,379 100
S300F 28 o1 283 3
S300F 32 o1 301 3
V255M 211 5 9,427 91
V255M 156 4 8,994 87
Mock 16 0 19 0
1Solubilized microsomes from insect cells mock-infected or infected with
baculovirus containing GGCX cDNA variants were assayed for expressed
enzyme activity in the presence or absence of Factor X propeptide. Two
independent viruses of each mutant were analyzed. The microsomes were
also assayed by a quantitative western analysis, and the activities shown
are normalized for equivalent amounts of carboxylase protein.
2The percent value was determined after subtracting the background
observed in the mock-infected sample, the corresponding wild-type
activity being 100%.
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Figure 4. Immunohistochemistry of skin in patients with PXE-like cutaneous lesions with mineralization (Patients III-1, III-3 and II-3) as well as in normal skin
(control). Monoclonal antibodies recognizing the undercarboxylated (ucMGP; a–d) and carboxylated (cMGP; e–h) forms of matrix gla protein, as well as
polyclonal antibodies for fetuin-A (i–l) and osteonectin (m–p) were utilized. The secondary antibodies, biotin-conjugated anti-IgG, were recognized by avidin-
alkaline phosphatase conjugates and visualized by incubation with an alkaline phosphatase substrate yielding red color. Scale bar¼0.1 mm.
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(Figure 4i–k and m–o). In contrast, no staining was observed in
normal skin (Figure 4l and p).
In addition to tissue analysis, we utilized a competitive
ELISA to quantitatively determine the levels of total ucMGP in
plasma, based on an antibody that recognizes both the
phosphorylated and unphosphorylated forms of ucMGP. The
results revealed that the father (II-1) and brother (III-2) of
the proband in this family had values that were at the lower
end of those in five unrelated controls (mean±standard
deviation, 3,902±612 pM; Figure 5a). All the other members
of the family showed reduced values, apparently reflecting
deposition of ucMGP in the mineralized tissues. Assay of
non-phosphorylated forms of ser-ucMGP, which display free
serine residues recognized by a specific antibody, revealed
that the proband (III-3) and her sister (III-1) had values far
exceeding those of the control group (432.0 pM; n¼ 100, CV
6%), whereas the values in plasma from other members of the
family were low (Figure 5b). These findings, together with
similar assays of ser-cMGP in the patients’ plasma, showed a
markedly increased ratio of ser-ucMGP/ser-cMGP in the
proband and her sister (2.0 and 1.9, respectively), whereas
the values of the rest of the family were within the normal
range (mean 0.32; Figure 5c). Thus, the proband and her
sister clearly show an abundance of undercarboxylated and
non-phosphorylated species of MGP. As these forms of MGP
are inactive, unable to prevent aberrant mineralization, these
findings explain the tissue mineralization shown in the skin
by specific histopathologic stains (see above).
DISCUSSION
In this study, we have detailed a family with PXE-like
cutaneous features, in association with combined coagula-
tion factor disorder. Specifically, the proband’s mother and
her maternal aunt presented with skin manifestations typical
of PXE, such as yellowish papules and/or plaques with dot-
like depressions characterized by mineralization of elastic
fibers in the reticular and mid dermis as viewed by light
microscopy. The proband herself and her sister were more
severely affected and they have significant sagging of the skin
with reduced elasticity and resilience and loss of recoil.
Histopathology of the skin from the proband and her sister
revealed distinct mineralization of elastotic structures in the
mid dermis, as visualized with von Kossa and Alizarin red
stains. These clinical and histopathologic findings in the skin
are consistent with PXE (Ringpfeil et al., 2001; Neldner and
Struk, 2002; Uitto and Ringpfeil, 2007).
A second phenotypic feature in this family is deficiency of
vitamin K-dependent coagulation factors, particularly Factor
X, which are synthesized in the liver and depend on vitamin
K for their function (Berkner, 2005). Combined deficiency of
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Figure 5. Quantitation of different forms of MGP in plasma by ELISA. (a) Total, both phosphorylated and non-phosphorylated forms of undercarboxylated
MGP (total ucMGP). (b) Assay of non-phosphorylated, undercarboxylated forms of MGP (ser-ucMGP). (c) The ratio of ser-ucMGP/ser-cMGP. The dashed
lines in (a and b) represent the mean of control specimens and the coefficient of variation (CV) is indicated by the stippled areas (CV¼15.7% in a, n¼ 5;
CV¼6.0% in b, n¼ 100).
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the vitamin K-dependent factors (vitamin K-dependent
coagulation factor deficiency, VKCFD) is an autosomal
recessive disorder, caused either by mutations in the GGCX
gene (type I: VKCFD1—OMIM no. 277450) on chromosome
2p12, or in the VKORC1 gene (type II: VKCFD2—OMIM no.
607473) on chromosome 16p11.2. These genes encode a
vitamin K-dependent carboxylase and vitamin K 2,3 epoxide
reductase, respectively (Wu et al., 1991; Li et al., 2004; Rost
et al., 2004a, b). Both enzymes are essential for posttransla-
tional g-glutamyl carboxylation of clotting factors, enabling
them to attach to the phospholipid bilayer of membranes as
an essential prerequisite for blood coagulation (Zhang and
Ginsburg, 2004).
To elucidate the molecular pathogenesis of these pheno-
types in this family, we initially sequenced the ABCC6 gene
in consideration of the presence of PXE-like cutaneous
findings. The recurrent mutation p.R1141X was found in
the DNA from the father, mother, the maternal aunt and the
younger brother, but not in the proband herself or her sister.
In addition, no other ABCC6 mutations could be disclosed in
this family. Considering the clinical finding of coagulation
disorder of the proband and her sister, we also sequenced the
GGCX and VKORC1 genes, in which mutations cause the
type I and type II vitamin K-dependent coagulation factor
deficiency disorders, respectively. Sequencing of the GGCX
gene revealed two distinct missense mutations in this family,
and specifically, mutations p.V255M in exon 7 and p.S300F
in exon 8 of the GGCX gene were identified. The proband
and her sister were compound heterozygotes for the two
GGCX missense mutations, whereas the proband’s father,
brother, her mother and maternal aunt were heterozygous for
one of the GGCX mutations only (Figure 1g). Sequencing of
the whole coding region of VKORC1 gene did not reveal any
pathogenic mutation.
Considering the genotype/phenotype correlations, the
proband and her sister were compound heterozygotes for
both GGCX missense mutations, potentially explaining their
hematologic findings. In addition, their skin findings resem-
ble those recently reported by Vanakker et al. (2007), in
which six patients were demonstrated to have both coagula-
tion factor deficiency and PXE-like skin changes because of
mutations in the GGCX gene. In contrast, the proband’s
father, brother, her mother and maternal aunt were hetero-
zygous for one of the GGCX mutations only, designating
them as carriers without clinical hematologic findings. The
latter individuals were also carriers of the ABCC6 nonsense
mutation p.R1141X. It should be noted that the mother and
her twin sister were heterozygous for one of the GGCX
missense mutation p.V255M and one ABCC6 nonsense
mutation p.R1141X, suggesting digenic inheritance of their
cutaneous findings. The occurrence of digenic inheritance,
although rare, is well established (see for example, Gao et al.,
2007; Gropman and Adams, 2007; Jin et al., 2008; Nozu
et al., 2008). The chance of a combination of mutations in the
ABCC6 and GGCX genes is difficult to calculate, because the
precise carrier frequency of the mutations in these genes is
not known. It should be noted, however, that in a cohort of
4300 families with PXE analyzed in our laboratory for
mutations in the ABCC6 gene, five individuals were hetero-
zygous carriers of a mutation (p.R1141X) in one ABCC6 allele
only, yet none of them carried a mutation in the GGCX gene
(unpublished). Thus, the combination of mutations reported
in this study in two different genes, yet resulting in PXE-like
phenotype, is rare. Finally, a recent study has suggested that
heterozygosity for a single mutation in the ABCC6 gene may
closely mimic PXE, particularly displaying ophthalmologic
findings (Martin et al., 2008).
To investigate the functional consequences of the carbox-
ylase mutants, WT and mutant proteins were expressed in
insect cells, which do not contain endogenous carboxylase
activity but synthesize active enzyme from exogenously
introduced cDNA. We tested for carboxylase activity in an
assay system that measures [14C]-CO2 incorporation into a
Glu-containing small peptide substrate in the presence or
absence of the Factor X propeptide. This propeptide regulates
the activity of carboxylases by tethering the vitamin
K-dependent proteins to the enzyme and by activating the
carboxylase (Knobloch and Suttie, 1987; Berkner, 2005). In the
absence of the propeptide, both mutant carboxylases showed
markedly reduced enzyme activity, less than 5% of the WT
activity. However, addition of the propeptide to the assay
system restored the activity of the p.V255M mutant to the WT
level, whereas the activity of the p.S300F remained low,B3%
of the WT. These in vitro findings clearly suggest that the
mutant enzymes may be functionally deficient in vivo, but the
mechanisms of inhibition may be distinct, and may involve
differential propeptide as well as substrate binding.
Until now, 11 families comprising a total of 20 patients
with PXE-like skin changes and/or vitamin K-dependent
coagulation factor deficiency, with 16 distinct mutations in
the GGCX gene, have been reported (Table 3). The functions
of the residues that are mutated are for the most part
unknown as only two mutants (p.L394R and p.W501S) have
been previously characterized to sufficiently reveal function.
Those analyses showed that Leu394 and Trp501 are part of
the carboxylase and propeptide-binding sites, respectively
(Lin et al., 2002; Mutucumarana et al., 2000, 2003). Both
mutations therefore influence the affinity of g-glutamyl
carboxylase for the vitamin K-dependent protein substrate.
To carry out the carboxylation, the enzyme must also bind
three other co-substrates, which are vitamin K, CO2 and O2,
but functional residues that interact with these substrates are
unknown (Berkner, 2005). Thus, the carboxylation reaction is
complex and only a few functional residues have been
identified. It will be of interest to determine the precise
mechanisms by which the p.V255M and p.S300F mutants
analyzed in the present study impair carboxylation. Never-
theless, these mutants are the first ones specific to PXE-like
cutaneous phenotype to have been tested for in vitro
carboxylase activity. The reduced activity in p.V255M and
p.S300F indicate the importance of Val255 and Ser300 to
carboxylation and can explain the coagulation disorder and
PXE-like cutaneous phenotype detected in the proband and
her sister.
Less apparent, and perhaps more complex, are the
mechanisms leading to cutaneous PXE-like phenotypes in
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this family. Mutations in the ABCC6 gene have been shown
to cause PXE, an autosomal recessive disorder (Ringpfeil
et al., 2006), but heterozygous carriers of mutations, such as
p.R1141X detected in the proband’s mother and aunt, are
asymptomatic (Wegman et al., 2005; Pfendner et al., 2007).
At the same time, the proband and her sister did not harbor
mutations in ABCC6, yet their skin lesions clearly showed
profound mineralization. These findings raise the hypothesis
that reduced carboxylase activity results in undercarboxyla-
tion of not only the coagulation factors but other proteins,
such as MGP, as well. MGP plays a critical role in preventing
aberrant mineralization but to be activated, this protein has to
be fully carboxylated whereas undercarboxylated forms of
the protein are inactive and can not prevent aberrant
mineralization (Price et al., 1998; Shearer, 2000). In fact,
skin biopsies from the proband and her sister depicted
preponderance of undercarboxylated MGP, when examined
by immunohistochemistry using specific antibodies that
distinguish the fully carboxylated and undercarboxylated
forms of the protein (Schurgers et al., 2005). Furthermore,
assay of total ucMGP in plasma, which has been recently
suggested to serve as a biomarker of cardiovascular
calcification (Cranenburg et al., 2008), was reduced in
patients with skin findings, apparently reflecting tissue
mineralization.
An intriguing observation in our family was the presence
of PXE-like cutaneous features, with profound mineralization,
in the proband’s mother and aunt. These two individuals
were heterozygous carriers of p.R1141X mutation in ABCC6
and p.V255M in GGCX. As heterozygous carriers of
p.R1141X in ABCC6 alone do not manifest PXE and GGCX
mutations with respect to coagulation disorder are recessive,
these findings suggest that the skin phenotype in these two
individuals may be because of digenic inheritance. In this
case, haploinsufficiency of the carboxylase activity and
reduced ABCC6 functions could be complementary or
synergistic. The reasons for the fact that the proband’s father
and her brother were heterozygous carriers of mutations in
the ABCC6 gene (p.R1141X) and the GGCX gene (p.S300F)
yet did not display any cutaneous findings are not clear.
Specifically, whereas both GGCX mutations resulted in
reduced enzyme activity, the reduction in case of protein
harboring the p.S300F mutation was more pronounced than
that of p.V255M. In this context, it should be noted that the
substrate employed in the carboxylase assay is a pentapep-
tide, Phe-Leu-Glu-Glu-Leu, and it is possible that the activity
measurements if carried out on full-length MGP as substrate
would show differential activity with these two mutant
enzymes. Finally, these two individuals have not been
examined by an ophthalmologist nor has a skin biopsy been
performed, because of their unwillingness to participate in
further studies. Consequently, the possibility that the father
and the brother of the proband may have subclinical, PXE-
associated features can not be rigorously excluded.
The findings of this study have potential implications
regarding the pathomechanisms of PXE, a multisystem
disorder with extensive tissue mineralization. Our results
suggest that undercarboxylation of MGP plays a critical role
in aberrant mineralization of tissues in PXE, a proposition that
has been supported by recent electron microscopic examina-
tion of skin of patients with PXE (Gheduzzi et al., 2007) and
analysis of the carboxylation status of MGP in Abcc6/ null
Table 3. Distinct mutations reported in the GGCX gene in patients with pseudoxanthoma elasticum-like skin
findings and/or VKCFD
Mutations Phenotype
Family (No)1 Age (years) Allele 1 Exon Allele 2 Exon PXE-like VKCFD References
I (4) NB p.L394R c.1209T4G 9 p.L394R c.1209T4G 9 NR + Brenner et al. (1998)
II (1) NB p.W501S c.1530G4C 11 p.W501S c.1530G4C 11 NR + Spronk et al. (2000)
III (1) 1 p.R485P c.1454G4C 11 Loss of exon 3 Intron 2G4T 3 NR + Rost et al. (2004a, b)
IV (1) 38 p.R485P c.1454G4C 11 p.H404P c.1239A4C 9 NR + Rost et al. (2006)
V (1) 2 p.W157R c.497T4C 4 p.T591K c.1800C4A 13 NR + Darghouth et al. (2006)
VI (1) 46 p.W493S c.1506G4C 112 p.W493S c.1506G4C 112 + + Vanakker et al. (2007)
VII (1) 67 p.R476C c.1454C4T 10 — — — + + Vanakker et al. (2007)
VIII (1) 32 p.R476H c.1455G4A 10 — — — + + Vanakker et al. (2007)
IX (2) 46, 44 p.Q374X c.1148C4T3 8 p.G537Y c.1339G4T4 12 + + Vanakker et al. (2007)
X (1) 40 p.F299S c.924T4C 8 p.G558R c.1700G4A 12 + + Vanakker et al. (2007)
XI (2) 16, 19 p.V255M c.791G4A 7 p.S300F c.927C4T 8 + + Present study
XI (2) 40 p.V255M c.791G4A 7 — — — + ND Present study
XI (2) 17, 39 p.S300F c.927C4T 8 — — — ND ND Present study
NB, new born; ND, not detected; NR, not reported; PXE, pseudoxanthoma elasticum; VKCFD, vitamin K-dependent coagulation factor deficiency.
1The numbers in parenthesis indicate the number of individuals depicting the combination of mutations in the family.
2This mutation was reported to reside in exon 12 (Vanakker et al., 2007).
3This mutation was reported as c.1149C4T (Vanakker et al., 2007).
4In the reference sequence (NM000821), this nucleotide resides in exon 10 and encodes a tryptophan.
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mice, which recapitulate the features of PXE (Jiang et al.,
2007; Li et al., 2007). How the absence of ABCC6, a putative
transmembrane transporter expressed primarily in the liver,
contributes to reduced g-glutamyl carboxylase of MGP
remains to be explored, but one possibility revolves around
cellular transport and redistribution of vitamin K, an
obligatory cofactor of g-glutamyl carboxylase (Berkner,
2005; Schurgers et al., 2007; Borst et al., 2008; Li et al.,
2008). Such notion would have broader implications for
aberrant tissue mineralization including pathologic pro-
cesses, such as arteriosclerosis, beyond PXE. Finally, the
ratio of ser-ucMGP/ser-cMGP was markedly elevated in
the proband and her sister, individuals with most severe
skin manifestations, including profound mineralization of
the dermis. This ratio may reflect vitamin K status of the
individual patient, and consequently, one could ascertain the
possibility that treatment with appropriate vitamin K prepara-
tions could ameliorate or even reverse tissue mineralization
in PXE, a currently intractable disorder.
MATERIALS AND METHODS
Patients
The patients were clinically evaluated at Washington University
School of Medicine (St. Louis Children’s Hospital and the Center for
Advanced Medicine) and at St. Louis University. Informed consent
was obtained from all patients. Skin biopsies were evaluated with
light microscopy using hematoxylin-eosin, von Kossa and Alizarin
red stains. Coagulation assays were performed on EDTA blood
samples and the activities of Factors II, VII, VIII, IX, and X were
measured in one-stage clotting assays.
Molecular analysis
Genomic DNA was isolated from peripheral blood samples
(QIAamp Blood Maxi kit; Qiagen Inc., Valencia, CA). PCR was
performed using 1.5 U Taq polymerase (Qiagen) mixed with 5 U
Optimase Taq polymerase (Transgenomic, Gaithersburg, MD) and
Q buffer (Qiagen), according to the manufacturers’ instructions. PCR
reactions contained 200 ng DNA as template and 20 ng of each
primer in a final volume of 50 ml.
The GGCX gene was analyzed using primers and PCR conditions
as previously described (Oldenburg et al., 2000). The ABCC6
sequences were analyzed using PCR primers as described previously
(Pfendner et al., 2007). For the detection of the deletion of exons
23–29, the primers described by Le Saux et al. (2001) were used. The
VKORC1 coding region was analyzed using primers described
previously (Darghouth et al., 2006).
The entire coding region and intron/exon boundaries of GGCX,
ABCC6 and VKORC1 were analyzed with direct sequencing using
an Applied Biosystems 3730 Sequencer (Applied Biosystems, Foster
City, CA). Within the exon 7 of the GGCX gene, the 791G-A
substitution abolished an Apal I restriction site. Digestion of the 243-
bp PCR product resulted in the case of the normal allele in 163- and
80-bp fragments, whereas the heterozygotes showed 243-, 163- and
80-bp bands.
For GGCX sequences the nucleotide numbers are derived from
cDNA (GenBank accession no. NM000821); the þ 1 corresponds to
the 28 with respect to the translation initiation codon. In the
ABCC6 gene, the þ 1 correspond to the A nucleotide in the ATG
translation initiation codon (GenBank accession no. AF076622). The
alignments of the GGCX protein sequences in different species were
generated with Clustal W program.
Construction and analysis of mutant carboxylase enzymes
Generation of carboxylase cDNAs with the individual mutations
p.V255M and p.S300F was accomplished using the Quick Change
XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) according
to the manufacturer’s instructions and using the following oligo-
nucleotide primers: p.V255M: (forward) CTGACTAGCCTGCTGGT
CATGCACTGGGGTGGGCTGCTG and (reverse) CAGCAGCCCA
CCCCAGTGCATGACCAGCAGGCTAGTCAG; p.S300F: (forward)
TTCAGCATTGGTATGTTCTTCTACGTCATGCTGGCCAGC and (re-
verse) GCTGGCCAGCATGACGTAGAAGAACATACCAATGCTGAA.
Briefly, a full-length GGCX cDNA was hybridized to the
indicated primers and subjected to Pfu polymerase (Stratagene)
extension. After 20 cycles of amplification, parental WT strands were
digested with the methyl-sensitive restriction enzyme DpnI, and
amplified mutant strands were self-ligated and used to transform
DH5a E. coli. A BamHI fragment containing the full-length cDNA
was isolated and subcloned into the baculovirus expression vector
pBacPak9 (Invitrogen Corp., Carlsbad, CA), and the cDNA was
sequenced on both strands. Baculoviruses containing each variant
were generated by cotransfecting SF21 cells with the plasmids and
Bsu36I-digested viral DNA (BacPAK6; Clontech, Palo Alto, CA) as
before (Rishavy et al., 2004). Virus was isolated from individual
plaques and screened for carboxylase expression by infecting cells,
preparing lysates and performing Western analysis using an antibody
against the C-terminus of the carboxylase (Berkner and McNally,
1997; Berkner and Pudota, 1998). Two independent viral isolates of
each mutant were then amplified and used in large-scale infections
to generate microsomes. The microsomes were solubilized (at
4 mg ml1) in 0.5% CHAPS, 0.1% phosphatidyl choline and then
assayed in a quantitative Western analysis to determine the amount
of carboxylase protein. Carboxylase activity was measured by
incubating the solubilized microsomes (40 mg) in 160 ml of 0.8 M
ammonium sulfate, 0.16% CHAPS, 0.16% phosphatidyl choline,
2.5 mM Phe-Leu-Glu-Glu-Leu peptide as substrate, 50 mM BES (pH
6.9), 2.5 mM dithiothreitol, 1.3 mM [14C]-CO2 and 200 mM vitamin K
hydroquinone. Samples were assayed in duplicate and the assays
were performed either in the presence or absence of 10 mM Factor X
propeptide (Berkner, 2005).
Immunohistochemistry
Immunohistochemistry was performed on tissues embedded in
paraffin. Sections of 5mm were stained with moAb-cMGP
(4.5 mg ml1; monoclonal antibody towards the carboxylated forms
of human MGP), moAb-ucMGP (4.5 mg ml1; monoclonal antibody
towards the non-carboxylated forms of human MGP) (Schurgers
et al., 2005), goat anti-human fetuin-A (1:40; R&D Systems,
Minneapolis, MN) and rabbit anti-human osteonectin (1:1,000;
Calbiochem, San Diego, CA), respectively. Immunostaining was
performed using either biotinylated rabbit anti-mouse IgG (Dako,
Carpinteria, CA) or biotinylated rabbit anti-goat IgG (Dako) or
biotinylated swine anti-rabbit IgG (Dako) as secondary antibody
(60 minutes at room temperature), followed by incubation with
avidin-linked alkaline phosphatase complex (30 minutes at room
temperature; Dako); staining was performed using the Vector
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Red Alkaline Phosphatase Substrate kit I (Vector Laboratories,
Burlingame, CA). Sections were counterstained with hematoxylin
and mounted with Permount (Fisher, Fair Lawn, NJ). Controls for the
immunoreactions were performed by omitting the primary antibody
or by incubating the sections with nonimmune sera instead of the
primary antibody.
ELISA for plasma MGP
A conformation-specific monoclonal antibody (Schurgers et al.,
2005) was used to construct an ELISA for detection of total ucMGP in
plasma, as described elsewhere (Cranenburg et al., 2008). Two
additional sandwich ELISAs were developed at VitaK BV (Maastricht,
the Netherlands) to quantitatively measure the non-phosphorylated
forms of both ucMGP and cMGP in plasma. In brief, a monoclonal
antibody specific for non-phosphorylated-MGP (moAb serMGP) was
coupled to the microtiter plate (5mg ml1). After incubation, non-
specific sites were blocked using a solution of 2% BSA in Hepes/
NaCl buffer. After stringent washing, standards, controls, or
experimental samples were applied, diluted in 0.2% protifar in
Hepes/NaCl buffer. The second antibody (either directed against the
uncarboxylated or carboxylated conformation of MGP) was
biotinylated and diluted in 0.2% protifar Hepes/NaCl buffer. After
stringent washing, streptavidin in 0.5% BSA/Hepes/NaCl was added
and staining was carried out using the substrate TMB (30 minutes at
room temperature). The reaction was stopped with 2 N H2SO4, and
the OD was measured at 450 nm.
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adhere to the Declaration of Helsinki Principles.
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